RADX Stock Summary and Trading Ideas (Radiopharm Theranostics Limited - American Depositary Shares | NASDAQ:RADX)

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.

As of August 21, 2026, RADX stock price climbed to $2.44 with 48,565 million shares trading.

RADX has a beta of 0.54, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.01 to the broad based SPY ETF.

RADX has a market cap of $18.98 million. This is considered a Sub-Micro Cap stock.

RADX has underperformed the market in the last year with a price return of -56.8% while the SPY ETF gained +21.7%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.0% and -12.9%, respectively, while the SPY returned +3.4% and -1.0%, respectively.

RADX support price is $2.11 and resistance is $2.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.